GIP/GLP-1 RA Phase III Success; USPSTF Looking for Input

(MedPage Today) -- Eli Lilly said the SURPASS-3 and SURPASS-5 phase III clinical trials showed that the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide significantly reduced HbA1c...